CEO
VG
Veritie Group
Veritie Diagnostics utilizes Raman Spectroscopy and Surface Enhanced Raman Spectroscopy (SERS) to provide low-cost, non-invasive in vitro diagnostics for high-incidence diseases, starting with breast cancer detection through urine analysis. This technology enables rapid, accurate results at the point-of-care, reducing the need for invasive procedures and unnecessary antimicrobial use.
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Current methods for breast cancer detection often involve invasive procedures and expensive equipment, leading to patient discomfort and delayed diagnoses, particularly in resource-limited settings. The need for specialized facilities and trained personnel further restricts accessibility to timely and accurate screening.
Solution
Veritie Diagnostics is developing a non-invasive in vitro diagnostic platform leveraging Raman Spectroscopy and Surface Enhanced Raman Spectroscopy (SERS) for the detection of high-incidence diseases, initially focusing on breast cancer. By analyzing urine samples, the technology aims to provide rapid and accurate results at the point-of-care. This approach seeks to minimize the necessity for invasive procedures, reduce healthcare costs, and improve patient outcomes through earlier detection. The platform combines photonics and machine learning to identify disease-specific biomarkers in a readily accessible bodily fluid.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and hospitals seeking cost-effective and non-invasive screening tools for breast cancer, as well as women requiring routine breast cancer screening.
Features
- Utilizes Raman Spectroscopy and Surface Enhanced Raman Spectroscopy (SERS) for biomarker detection.
- Employs machine learning algorithms to analyze spectral data and improve diagnostic accuracy.
- Designed for point-of-care testing, enabling rapid results and decentralized access.
- Non-invasive urine sample analysis eliminates the need for biopsies or other invasive procedures.
- Aims to provide a low-cost alternative to traditional breast cancer screening methods.